Lupus Science & Medicine

Proteomic analysis reveals angiogenesis-related plasma proteins associated with pre-eclampsia in SLE

Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE.
lupus.bmj

Cutaneous lupus concerns from the patient perspective: a qualitative study

Objective There is a need to identify concerns unique to patients with cutaneous lupus erythematosus (CLE), which may not be captured by current common-practice dermatological quality-of-life tools.
lupus.bmj

Dietary Intervention for Systemic Lupus Erythematosus patients based on HLA-DQ2 and DQ8 genotyping (DISH): a protocol for a randomised controlled study

Introduction SLE is a chronic autoimmune disease that is influenced by both genetic and environmental factors, one of which is diet. Dietary intervention plays a role in the management of SLE, and ...
lupus.bmj

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...
lupus.bmj

Risk factors and outcomes of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a retrospective-multicentre cohort study and systematic literature review

Objective Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological diagnosis that can be associated with SLE. The clinical presentation, risk factors and outcomes of PRES in ...
lupus.bmj

1502 Genetic predisposition to lupus across ancestries has >300 separable genetic contributions: what we know today

Background Systemic lupus erythematosus (SLE) is a complex disease caused by interplay of genetic predisposition and environmental triggers. Strong genetic component in lupus supported by familial ...
lupus.bmj

Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus

Objectives Antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPLs) and clinical outcomes of thrombosis and/or obstetric morbidity and is associated with ...
lupus.bmj

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus

Objective This post hoc analysis compared anifrolumab 300 mg every 4 weeks with placebo on rash and arthritis measures with different stringency in patients with moderate to severe SLE (phase IIb; ...
lupus.bmj

83 Biib059, a monoclonal antibody targeting bdca2, demonstrates evidence of proof of biological activity in subjects with cutaneous lupus

Background and aims Type I interferons (IFN-I) are central to the pathogenesis of systemic lupus erythematosus (SLE). BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, upon ...
lupus.bmj

Table of contents

LP-198 Clinical response by subgroups in patients with systemic lupus erythematosus (SLE) receiving standard of care treatment plus placebo (SOC+PBO): a post hoc analysis from clinical trial data (6 ...
lupus.bmj

Table of contents

12th Annual Meeting of the Lupus Academy; Virtual Pre-meeting: September 1, 2023; Hybrid Annual Meeting (Barcelona): September 8–10, 2023 ...